Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Dec;70(6):1211–1216. doi: 10.1038/bjc.1994.475

Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen.

I N Fernando 1, J C Titley 1, T J Powles 1, M Dowsett 1, P A Trott 1, S E Ashley 1, H T Ford 1, M G Ormerod 1
PMCID: PMC2033693  PMID: 7981079

Abstract

Sequential fine-needle aspirates (FNAs) for cytodiagnosis and flow cytometry were taken from 21 patients with primary breast carcinoma at intervals ranging from 1 to 3 months after the commencement of first-line tamoxifen therapy. Nine patients achieved a sustained complete or near complete response over a 3-9 month period. The tumour cells from seven out of nine of these patients were initially aneuploid, while the remaining two patients had diploid tumours. An analysis of sequential FNAs showed that, in three out of the seven aneuploid tumours, only benign epithelial cells could be detected by cytology in the post-tamoxifen sample. In the remaining six cases, including the two diploid tumours, there was no change in ploidy but a reduction in S-phase fraction (SPF) to approximately 50% of the pretreatment level. In all cases, these changes in ploidy or SPF were seen with a mean lead time of 4 months before the tumour had reached clinical complete remission. None of these patients have relapsed after a mean follow-up period of 18 months. The tumours of 12 patients achieved no more than a temporary partial response to primary tamoxifen therapy. In seven out of eight of these cases, which were all initially aneuploid, sequential FNAs during tamoxifen therapy revealed either an increase or no change in the SPF with the tumour remaining aneuploid. In the remaining four cases the tumours were all recorded as being diploid in the pretreatment sample. However, although three of these cases had a temporary partial response to tamoxifen, an aneuploid component was picked up in repeat sequential FNAs with a mean lead time of 5 months before clinical confirmation of eventual disease progression. We conclude that changes in ploidy and SPF detected by flow cytometry may predict initial response and the likelihood of relapse of breast tumours to tamoxifen before clinical changes become evident. These data justify a larger study.

Full text

PDF
1211

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra J. C., Lippman M. E., Thompson E. B., Simon R., Barlock A., Green L., Huff K. K., Do H. M., Aitken S. C., Warren R. Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer. 1980 Mar;16(3):323–331. doi: 10.1016/0014-2964(80)90348-5. [DOI] [PubMed] [Google Scholar]
  2. Baildam A. D., Zaloudik J., Howell A., Barnes D. M., Moore M., Sellwood R. A. Effect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast. Br J Cancer. 1987 May;55(5):561–566. doi: 10.1038/bjc.1987.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brünner N., Bronzert D., Vindeløv L. L., Rygaard K., Spang-Thomsen M., Lippman M. E. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res. 1989 Mar 15;49(6):1515–1520. [PubMed] [Google Scholar]
  4. Campbell F. C., Blamey R. W., Elston C. W., Morris A. H., Nicholson R. I., Griffiths K., Haybittle J. L. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. 1981 Dec 12;2(8259):1317–1319. doi: 10.1016/s0140-6736(81)91341-6. [DOI] [PubMed] [Google Scholar]
  5. Clarke R. B., Laidlaw I. J., Jones L. J., Howell A., Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer. 1993 Mar;67(3):606–611. doi: 10.1038/bjc.1993.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Erhardt K., Auer G. Mammary carcinoma: DNA analysis in areas showing different histological features in the same tumor. Acta Pathol Microbiol Immunol Scand A. 1986 Jan;94(1):21–28. doi: 10.1111/j.1699-0463.1986.tb02959.x. [DOI] [PubMed] [Google Scholar]
  7. Fisher B., Redmond C., Brown A., Wickerham D. L., Wolmark N., Allegra J., Escher G., Lippman M., Savlov E., Wittliff J. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol. 1983 Apr;1(4):227–241. doi: 10.1200/JCO.1983.1.4.227. [DOI] [PubMed] [Google Scholar]
  8. Greenebaum E., Koss L. G., Sherman A. B., Elequin F. Comparison of needle aspiration and solid biopsy technics in the flow cytometric study of DNA distributions of surgically resected tumors. Am J Clin Pathol. 1984 Nov;82(5):559–564. doi: 10.1093/ajcp/82.5.559. [DOI] [PubMed] [Google Scholar]
  9. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  10. Kallioniemi O. P. Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry. 1988 Mar;9(2):164–169. doi: 10.1002/cyto.990090211. [DOI] [PubMed] [Google Scholar]
  11. Kute T. E., Muss H. B., Hopkins M., Marshall R., Case D., Kammire L. Relationship of flow cytometry results to clinical and steroid receptor status in human breast cancer. Breast Cancer Res Treat. 1985;6(2):113–121. doi: 10.1007/BF02235742. [DOI] [PubMed] [Google Scholar]
  12. Mullen P., Miller W. R. Variations associated with the DNA analysis of multiple fine needle aspirates obtained from breast cancer patients. Br J Cancer. 1989 May;59(5):688–691. doi: 10.1038/bjc.1989.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nowell P. C. The clonal evolution of tumor cell populations. Science. 1976 Oct 1;194(4260):23–28. doi: 10.1126/science.959840. [DOI] [PubMed] [Google Scholar]
  14. Osborne C. K., Boldt D. H., Estrada P. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 1984 Apr;44(4):1433–1439. [PubMed] [Google Scholar]
  15. Osborne C. K., Yochmowitz M. G., Knight W. A., 3rd, McGuire W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2884–2888. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  16. Paridaens R., Sylvester R. J., Ferrazzi E., Legros N., Leclercq G., Heuson J. C. Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2889–2895. doi: 10.1002/1097-0142(19801215)46:12+<2889::aid-cncr2820461430>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  17. Prey M. U., Meyer J. S., Stone K. R., McDivitt R. W. Heterogeneity of breast carcinomas determined by flow cytometric analysis. J Surg Oncol. 1985 May;29(1):35–39. doi: 10.1002/jso.2930290111. [DOI] [PubMed] [Google Scholar]
  18. Remvikos Y., Vielh P., Padoy E., Benyahia B., Voillemot N., Magdelénat H. Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation. Br J Cancer. 1991 Sep;64(3):501–507. doi: 10.1038/bjc.1991.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rubens R. D., Hayward J. L. Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2922–2924. doi: 10.1002/1097-0142(19801215)46:12+<2922::aid-cncr2820461435>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  20. Sutherland R. L., Green M. D., Hall R. E., Reddel R. R., Taylor I. W. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol. 1983 May;19(5):615–621. doi: 10.1016/0277-5379(83)90177-3. [DOI] [PubMed] [Google Scholar]
  21. Young P. C., Ehrlich C. E., Einhorn L. H. Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2961–2963. doi: 10.1002/1097-0142(19801215)46:12+<2961::aid-cncr2820461444>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES